03 Profile
Hansard to 4 November 2026 · 31,174 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Rare diseases
Mary Carmichael
Head of Science & Technology Communications, Danaher Corporation
press citation on 1 topic since 5 Jan 2026 · last quoted 5 Jan 2026
02 Quoted on · 1 of 29 topics
Mary Carmichael: key facts
- Kind of voice
- Sector leader
- Role
- Head of Science & Technology Communications, Danaher Corporation
- Quoted on
- Rare diseases
- Tracked press citations
- 1
- Most recently quoted
- 5 Jan 2026
04 The signal · where Mary Carmichael sits on rare diseases
Ranked 25= of 231 voices quoted in the press on rare diseases, level with 206 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Vinay PrasadAcademicProfessor of Epidemiology and Biostatistics and Medicine; hematologist-oncologist, University of California, San Francisco (UCSF)4
- 1=David WeitzAcademicMallinckrodt Professor of Physics and of Applied Physics; Professor of Systems Biology, Harvard University (John A. Paulson School of Engineering and Applied Sciences)4
- 1=Tuomas KnowlesAcademic1920 Professor of Physical Chemistry, University of Cambridge4
- 25=Dr Sudheendra Rao N RAcademicMBBS, PhD, Scientific Advisor, Organization for Rare Diseases India1
- 25=Jared JoselynSector leaderSenior Vice-President, Global Head of Digital Health and Emerging Disruptive Growth Exploration (E.D.G.E.) at Sanofi1
- 25=Mary CarmichaelSector leaderHead of Science & Technology Communications, Danaher Corporation1
- 25=Vanessa Almendro-NavarroSector leaderVice President and Head of Science & Technology Innovation, Danaher Corporation1
- 25=Vik SharmaSector leaderFounder, MiraKare1
Showing the leaders and the ranks around 25=, of 231 voices · See every voice on the topic →
05 On the record · press
What Mary Carmichael has said
- nationalpress.org1
Where Mary Carmichael has been quoted
- 01How AI Is Transforming Rare Disease Researchnationalpress.org · 5 Jan 2026
Verbatim
“It can match patients to potential diagnoses or to clinical trials more quickly. It can simulate the way that disease works, the pathobiology, the mechanisms, the treatment responses, and that way it can help researchers prioritize therapies and move faster.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.